MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Current Liabilities
All obligations due within one year.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 108.6% from a year ago
Total current liabilities stood at $25.17M at the end of Q3 FY2026, up 108.6% from a year earlier and up 6.4% from the prior quarter. Over 3 fiscal years it compounded at +65.3% a year.
Context
- Total current liabilities amounted to 5.0% of total assets at the end of Q3 FY2026, up 2.0 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +108.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15.5M USD
- Year-over-year change
- +40.2%
- 3-year CAGR
- +65.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.5M | +40.2% |
| FY2024 | 2024-12-31 | 11.05M | +181.5% |
| FY2023 | 2023-12-31 | 3.93M | +14.4% |
| FY2022 | 2022-12-31 | 3.43M | — |
Total Current Liabilities vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +108.6% is the 2nd highest of 8, against a peer median of +24.7%.
- Total current liabilities amounts to 5.0% of total assets for MBX, versus a peer median of 20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €549.08M EUR | -44.3% | +14.2% | 22.6% | |
| Sep 2026 | $150.89M USD | +44.7% | +38.6% | 34.1% | |
| Mar 2026 | $118.59M USD | +24.7% | +14.2% | 30.3% | |
| Jun 2026 | $109.66M USD | +242.9% | +51.7% | 21.0% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $83.65M USD | — | — | 6.9% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $25.17M USD | +108.6% | +65.3% | 5.0% |
| Mar 2026 | $11.32M USD | +15.6% | -4.2% | 3.4% | |
| Mar 2026 | $10.56M USD | +92.3% | +49.2% | 3.9% | |
| Mar 2026 | $9.29M USD | -53.1% | -16.5% | 20.0% | |
| Peer median (excluding MBX) | — | +24.7% | +14.2% | 20.5% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.